Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 80 Significant unmet need in obesity management Insufficient treatment options All people with obesity Significant gaps in obesity treatment Mean weight loss 100% 30% People diagnosed People Rx treated* 4% Source: Diagnosis rate, Practice Fusion March 2014 & Treatment rate, Understanding the Treatment Dynamics of the Obesity Market, IMS Database (NPA), August 2014 *Rx prescription, ie treated with anti-obesity medication (AOM) changing diabetes® Medium High MOT Bariatric surgery Anti-obesity medication with weight loss of 5-10% Diet and exercise Low Medium Complexity of treatment High novo nordisk

View entire presentation